

# Mitochondrial disease genetics


Jelle van den Ameele

MRC Mitochondrial Biology Unit,  
Department of Clinical Neurosciences  
University of Cambridge

[jv361@cam.ac.uk](mailto:jv361@cam.ac.uk), [jelle.vandenameele@nhs.net](mailto:jelle.vandenameele@nhs.net)



MRC  
Mitochondrial  
Biology Unit





### Neurology:

Patrick Chinnery  
Rita Horvath  
Jelle van den Ameele  
Katherine Schon  
Catarina Olimpio  
Ignazio Arena  
May Yung Tiet



@cam\_mito

<https://www-neurosciences.medschl.cam.ac.uk/mitocamb/>

### Ophthalmology:

Patrick Yu Wai Man  
Benson Chen  
Xuehao Cui



CAMBRIDGE  
CLINICAL VISION  
LABORATORY


### Research and clinic support:

Heather Biggs  
Emma Harrison  
Elizabeth Ashby  
Charlotte Addy  
Katrina Dedman

[jv361@cam.ac.uk](mailto:jv361@cam.ac.uk)  
[jelle.vandenameele@nhs.net](mailto:jelle.vandenameele@nhs.net)  
[add-tr.mitoteam@nhs.net](mailto:add-tr.mitoteam@nhs.net)



Cambridge Clinical Mitochondrial Research Group



# Outline

## Case 1/2: Stroke-like episodes

- What are mitochondria
- Oxidative phosphorylation
- Inheritance of primary mitochondrial disease
- Mitochondrial disease overview and classical syndromes
- The mitochondrial genome (1)

## Case 3: CPEO

- The mitochondrial genome (2): heteroplasmy

## Case 4: Nuclear or mitochondrial?

- mtDNA maintenance disorders
- A few more classical syndromes


# Case 1

# MELAS: Mitochondrial encephalomyopathy with lactic acidosis and *stroke-like episodes*


Typical (diagnostic) features:

- Stroke-like episodes <40y
  - Seizures and/or dementia
  - Ragged-red fibres (muscle biopsy), lactic acidosis
- + many additional features: Diabetes mellitus, cardiomyopathy, hearing loss, pigmentary retinopathy, ataxia,...

Most frequently due to m.3243A>G mutation in the mitochondrial DNA (leucine tRNA, MT-TL1)




# Approach to a patient with suspected mitochondrial disease



## Case 2: Stroke-like episodes




# Prevalence of mitochondrial disease




~1/5,000 adults affected by mitochondrial disease

Most frequent type of inherited neurological disease,  
but many different genes and often complex clinical presentation

# Mitochondria



Mitochondria



Primary (genetic)  
mitochondrial disease

Mitochondrial contribution  
to common disease

# Inheritance of primary mitochondrial disease


Nuclear DNA (chromosomes)



Mitochondrial DNA  
maintenance

e.g. POLG, Twinkle,  
TYMP, RRM2B,...

Respiratory chain  
function and assembly



## Primary role specific to OXPHOS biogenesis

#### Secondary impact on OXPHOS ± other cellular functions

Fe-S cluster biogenesis <sup>e</sup>	Enzyme co-factors <sup>e</sup>	Protein quality control	Protein import/processing	Mitochondrial morphology <sup>e</sup>	Metabolite transport <sup>e</sup>	TCA cycle and metabolism	Metabolism of toxic compounds
<i>ABCB7</i>	<i>COASY</i>	<i>AFG3L2</i>	<i>AGK<sup>f</sup></i>	<i>CHCHD10</i>	<i>SLC19A2</i>	<i>ACO2</i>	<i>MDH2</i>
<i>BOLA3</i>	<i>FLAD1</i>	<i>CLPB</i>	<i>AIFM1</i>	<i>C19orf70 (QIL1)</i>	<i>SLC19A3</i>	<i>ALDH18A1</i>	<i>ECHS1</i>
<i>FDX1L</i>	<i>LIAS</i>	<i>CLPP</i>	<i>DNAJC19<sup>f</sup></i>	<i>DNM1L</i>	<i>SLC25A1</i>	<i>DLAT</i>	<i>ETHE1</i>
<i>FDXR</i>	<i>LIPT1</i>	<i>HSPD1</i>	<i>GFER</i>	<i>GDAP1</i>	<i>SLC25A3</i>	<i>DLD</i>	<i>PDHA1</i>
<i>FXN</i>	<i>LIPT2</i>	<i>LONP1</i>	<i>MIPEP</i>	<i>MFF</i>	<i>SLC25A4</i>	<i>FH</i>	<i>HIBCH</i>
<i>GLRX5</i>	<i>PANK2</i>	<i>SPG7</i>	<i>PMPCA</i>	<i>MFN2</i>	<i>SLC25A12</i>	<i>HAAO</i>	<i>L2HGDH</i>
<i>IBA57</i>	<i>TPK1</i>	<i>YME1L1</i>	<i>TIMM8A</i>	<i>MSTO1</i>	<i>SLC25A19</i>	<i>IDH3A</i>	<i>NAXE</i>
<i>ISCA2</i>			<i>TIMM50</i>	<i>OPA1</i>	<i>SLC25A24</i>	<i>IDH3B</i>	<i>TXN2</i>
<i>ISCU</i>				<i>SACS</i>	<i>SLC25A26</i>	<i>KYNU</i>	<i>PPA2</i>
<i>LYRM4</i>	Lipid modification/homeostasis		Apoptosis/Autophagy <sup>e</sup>	<i>SLC25A46<sup>g</sup></i>	<i>SLC25A32</i>	Unclear function <sup>e</sup>	
<i>NFS1</i>					<i>SLC25A42</i>		
<i>NFU1</i>				<i>STAT2</i>	<i>SLC39A8</i>		
	<i>ATAD3A</i>	<i>PNPLA8</i>	<i>HTRA2</i>		<i>MICU1</i>	<i>APOPT1</i>	<i>OPA3</i>
	<i>CHKB</i>	<i>SERAC1</i>	<i>VPS13C</i>		<i>MICU2</i>	<i>CEP89</i>	<i>RTN4IP1</i>
	<i>PLA2G6</i>	<i>TAZ</i>			<i>MPC1</i>	<i>C19orf12</i>	<i>SFXN4</i>
		<i>PNPLA4</i>				<i>C1QBP</i>	<i>TMEM65</i>
						<i>FBXL4</i>	


# Clinical features of mitochondrial disorders

Cardiomyopathy




Ophthalmoplegia / ptosis

Liver Failure




Encephalopathy  
Epilepsy / dementia  
Migraine


Diabetes





Gonadal failure




Parkinsonism



Dysphagia  
Dysmotility




Axonal  
sensori-motor  
neuropathy



Myopathy


Deafness



Ataxia



Migraine





# Classical syndromes

- Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS)
- Leber's hereditary optic neuropathy (LHON)
- Chronic progressive external ophthalmoplegia (CPEO)
- Kearns-Sayre Syndrome
- Pearson Syndrome
- Leigh Syndrome
- Mitochondrial inherited diabetes and deafness (MIDD)
- Myoclonic epilepsy with ragged red fibers (MERRF)
- Neuropathy, ataxia, retinitis pigmentosa (NARP)
- Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)

# The mitochondrial genome (1)

- Circular genome
- Contributes to OxPhos and mitochondrial translation
- Under control of nuclear genome
- Maternal inheritance
- Many copies in each cell






### Characteristics of Mitochondrial Inheritance


- Mitochondria are inherited from the mother.
- All offspring of an affected or carrier female are at risk of being affected.
- All daughters of an affected or carrier female are at risk of transmitting the condition.
- Affected males cannot pass the condition to any of their children.

# Maternal inheritance of mtDNA

Nuclear DNA inherited from both mother and father



Mitochondrial DNA inherited only from mother



# Casus 3

# Klinische diagnose: Kearns-Sayre Syndrome

Frequent klinisch beeld bij een patient met een single mtDNA deletion:

1. Retinitis pigmentosa
2. CPEO
3. Hartritme stoornissen
- (4. begin <20 jaar)

Vaak met:

Ataxie, verstandelijke beperking of dementie, doofheid, Myopathie, Gastro-intestinale problemen, ...

Klinisch beeld vaak gecorreleerd met grootte van de mtDNA deletie en heteroplasmy level.

**Retinitis Pigmentosa, External Ophthalmoplegia, and Complete Heart Block**

*Unusual Syndrome with Histologic Study in One of Two Cases*

THOMAS P. KEARNS, M.D., and GEORGE P. SAYRE, M.D., Rochester, Minn.





Fig. 1 (Case 1).—Patient with retinitis pigmentosa, external ophthalmoplegia, and atrioventricular heart block.

# Chronic progressive external ophthalmoplegia (CPEO)

Down



Up



Right




Left



+ ptosis (droopy eyelids)




# Approach to a patient with suspected mitochondrial disease



# Case 3: mtDNA heteroplasmie (of: waarom nog steeds een spierbiopsie?)

*Example COX-SDH staining  
(patient data removed for sharing)*





Thanks to Rob Taylor, Newcastle

# mtDNA heteroplasmie (of: waarom nog steeds een spierbiopsie?)


## Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies

I. J. Holt, A. E. Harding & J. A. Morgan-Hughes




# The mitochondrial genome (2)

- Circular genome
- Contributes to OxPhos and mitochondrial translation
- Under control of nuclear genome
- Maternal inheritance
- Many copies in each cell
  - Heteroplasmy vs homoplasmy
  - Heterogeneity in space and time
  - Genetic bottleneck




Brain of a heteroplasmic Drosophila strain





smFISH for wild-type mtDNA  
smFISH for mutant mtDNA

# mtDNA heteroplasmy



# Novel ways to detect (universal?) heteroplasmy






## Mitochondrial Inheritance

◻ ○ Unaffected

■ ● Affected

○○ Normal Mitochondria


●● Abnormal Mitochondria




### Characteristics of Mitochondrial Inheritance


- Mitochondria are inherited from the mother.
- All offspring of an affected or carrier female are at risk of being affected.
- All daughters of an affected or carrier female are at risk of transmitting the condition.
- Affected males cannot pass the condition to any of their children.

# Heteroplasmy shifts over time between generations: Mitochondrial bottleneck






m.3243A>G  
'MELAS'




# Case 4: Nuclear or mitochondrial?

# Approach to a patient with suspected mitochondrial disease



# Inheritance of primary mitochondrial disease


Nuclear DNA (chromosomes)



Mitochondrial DNA  
maintenance

e.g. POLG, Twinkle,  
TYMP, **RRM2B**,...

Respiratory chain  
function and assembly




**Table 2 | Defects of mtDNA maintenance**

Mutated gene	mtDNA depletion	Multiple mtDNA deletions
<i>TK2</i>	Infantile or adult myopathy SMA phenocopy	Adult autosomal recessive PEO
<i>DGUOK</i>	Infantile hepato-cerebral syndrome	Adult myopathy±PEO
<i>PEO1</i>	Hepato-cerebral syndrome Infantile-onset spinocerebellar ataxia	Adult autosomal dominant PEO-plus
<i>SUCLA2</i>	Infantile encephalomyopathy	—
<i>SUCLG1</i>	Infantile encephalomyopathy Methylmalonic aciduria	—
<i>RRM2B</i>	Infantile encephalomyopathy	Adult autosomal dominant or autosomal recessive PEO-plus
<i>MPV17</i>	Infantile hepatocerebral syndrome Navajo neurohepatopathy	Adult autosomal recessive PEO-plus
<i>TYMP</i>	Mitochondrial neurogastrointestinal encephalomyopathy	Mitochondrial neurogastrointestinal encephalomyopathy
<i>POLG</i>	Hepato-cerebral syndrome (Alpers syndrome)	Adult autosomal dominant or autosomal recessive PEO-plus; SANDO; MIRAS
<i>POLG2</i>	—	Adult autosomal dominant PEO
<i>ANT1</i>	—	Adult autosomal dominant PEO-plus
<i>OPA1</i>	—	DOA; PEO-plus
<i>MFN2</i>	—	DOA-plus
<i>GFER</i>	—	Congenital cataract, encephalomyopathy

Abbreviations: DOA, dominant optic atrophy; MIRAS, mitochondrial recessive ataxia syndrome; mtDNA, mitochondrial DNA; PEO, progressive external ophthalmoplegia; SANDO, sensory ataxic neuropathy, dysarthria and ophthalmoparesis; SMA, spinal muscular atrophy.

# Mutation of *POLG* is associated with progressive external ophthalmoplegia characterized by mtDNA deletions


Gert Van Goethem, Bart Dermaut, Ann Löfgren, Jean-Jacques Martin & Christine Van Broeckhoven *Nature Genetics* 28, 211–212 (2001) | [Cite this article](#)

# Mutations of Mitochondrial DNA Polymerase γA Are a Frequent Cause of Autosomal Dominant or Recessive Progressive External Ophthalmoplegia

Eleonora Lamantea, MSc,<sup>1</sup> Valeria Tiranti, PhD,<sup>1</sup> Andreina Bordoni, BSc,<sup>2</sup> Antonio Toscano, MD,<sup>3</sup> Francesco Bono, MD,<sup>4</sup> Serena Servidei, MD,<sup>5</sup> Alex Papadimitriou, MD,<sup>6</sup> Hans Spelbrink, PhD,<sup>7</sup> Laura Silvestri, PhD,<sup>8</sup> Giorgio Casari, PhD,<sup>8</sup> Giacomo P. Comi, MD,<sup>2</sup> and Massimo Zeviani, MD, PhD<sup>1</sup>

One form of familial progressive external ophthalmoplegia with multiple mitochondrial DNA deletions recently has been associated with mutations in *POLG1*, the gene encoding pol γA, the catalytic subunit of mitochondrial DNA polymerase. We screened the *POLG1* gene in several PEO families and identified five different heterozygous missense mutations of *POLG1* in 10 autosomal dominant families. Recessive mutations were found in three families. Our data show that mutations of *POLG1* are the most frequent cause of familial progressive external ophthalmoplegia associated with accumulation of multiple mitochondrial DNA deletions, accounting for approximately 45% of our family cohort.

Ann Neurol 2002;52:211–219




# An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region

Massimo Zeviani\*, Serenella Servidei†, Cinzia Gellera\*,  
Enrico Bertini†, Salvatore DiMauro†  
& Stefano DiDonato\*

\* Istituto Neurologico 'C. Besta', Laboratory of Biochemistry and Genetics,  
11 via Celoria, 20133 Milano, Italy

† Department of Neurology, Catholic University, viale Gemelli,  
00100 Roma, Italy

‡ Department of Neurology, Columbia University, 630 West 168th Street,  
New York, 10032, USA



van den Ameele et al., *Semin Cell Dev Biol*, 2019.




FIG. 1 Family pedigree. Solid symbols indicate clinically affected individuals. Barred symbols indicate deceased individuals. Arrows indicate the probandi. Onset of the disease is invariably in adult age. Thus, clinical attribution of the individuals in IV, who are still in infancy, is uncertain. Diamond symbols indicate siblings of unspecified sex. Number of siblings is also indicated.




FIG. 2 a Hybridization pattern of Pvull-digested total human muscle DNA, probed with radiolabelled human mtDNA (for detailed description of methods see ref. 2). Lanes 1 and 6 contain samples from two unrelated control subjects, with no muscle pathology. Lanes 2-5 contain samples from the probandi: lane 2, sample from patient III-4; lane 3, sample from patient III-7; lane 4, sample from patient III-7; lane 5, sample from patient II-6 (see Fig. 1). Size is in kb. b, Electrophoretic pattern of mtDNA fragments amplified by PCR. DNA was separated in a 7% polyacrylamide slab gel (40:1 acrylamide: bis-acrylamide in 1×TBE<sup>22</sup>). Lane 1, patient III-4; lane 2, patient III-6; lane 3, patient III-7; lane 4, patient II-6.


METHODS. One nanogram of total cellular DNA was used in each PCR experiment. The GeneAmp kit (Perkin-Elmer) was used in all the experiments. Synthetic oligonucleotides were: 5'-TGATTTAGATCTTTTCC-TTCC-3', 'forward primer' complementary to the sequence from bp 7,432 to bp 7,457 of the mtDNA L-strand<sup>5</sup>; 5'-TATTGACGGTACCATAAACTTG-3', 'reverse primer' corresponding to the sequence from bp 16,120 to bp 16,145 of the mtDNA L-strand (restriction sites for *Xba*I in forward primer and for *Kpn*I in reverse primer are in italics). In each experiment 25 cycles were performed. Time and temperature conditions for one cycle were as follows: heat-denaturation was at 95 °C for 2 min; primer-annealing was at 52 °C for 2 min; polymerase-extension was at 72 °C for 2 min in the first 4 cycles, 3 min in the following 6 cycles, and 4 min in the final 15 cycles.

**Table 2** | Defects of mtDNA maintenance

Mutated gene	mtDNA depletion	Multiple mtDNA deletions
<i>TK2</i>	Infantile or adult myopathy SMA phenocopy	Adult autosomal recessive PEO
<i>DGUOK</i>	Infantile hepato-cerebral syndrome	Adult myopathy±PEO
<i>PEO1</i>	Hepato-cerebral syndrome Infantile-onset spinocerebellar ataxia	Adult autosomal dominant PEO-plus
<i>SUCLA2</i>	Infantile encephalomyopathy	—
<i>SUCLG1</i>	Infantile encephalomyopathy Methylmalonic aciduria	—
<i>RRM2B</i>	Infantile encephalomyopathy	Adult autosomal dominant or autosomal recessive PEO-plus
<i>MPV17</i>	Infantile hepatocerebral syndrome Navajo neurohepatopathy	Adult autosomal recessive PEO-plus
<i>TYMP</i>	Mitochondrial neurogastrointestinal encephalomyopathy	Mitochondrial neurogastrointestinal encephalomyopathy
<i>POLG</i>	Hepato-cerebral syndrome (Alpers syndrome)	Adult autosomal dominant or autosomal recessive PEO-plus; SANDO; MIRAS
<i>POLG2</i>	—	Adult autosomal dominant PEO
<i>ANT1</i>	—	Adult autosomal dominant PEO-plus
<i>OPA1</i>	—	DOA; PEO-plus
<i>MFN2</i>	—	DOA-plus
<i>GFER</i>	—	Congenital cataract, encephalomyopathy


Abbreviations: DOA, dominant optic atrophy; MIRAS, mitochondrial recessive ataxia syndrome; mtDNA, mitochondrial DNA; PEO, progressive external ophthalmoplegia; SANDO, sensory atactic neuropathy, dysarthria and ophthalmoparesis; SMA, spinal muscular atrophy.

# Mitochondrial Neuro-Gastro-Intestinal Encephalomyopathy (MNGIE)



# MNGIE disease course

- Ultra-rare disease: prevalence estimated ~0.1-1/10<sup>6</sup>
- Progressive multisystem disorder
- Mean age at onset: 17.9 years (5 months to 43 years).
- **GI symptoms** (57% at onset; 100% at diagnosis)
- **Neurological symptoms** (43% at onset; 100% at diagnosis)
- **Mean age at death 35-37 years;**  
survival 100% <19 years; <5% after 50 years.
- Death is mainly due to cachexia,  
GI and liver complications



**Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Position paper on diagnosis, prognosis, and treatment by the MNGIE International Network**

Gastroenterology 2019;156:1525-1527

## BRIEF COMMUNICATION

### MyoNeuroGastroIntestinal Encephalopathy: Natural History and Means for Early Diagnosis

Giovanni Corazza,<sup>1</sup> Cécile Pagan,<sup>2</sup> Gaëlle Hardy,<sup>1</sup> Gérard Besson,<sup>1</sup> Anne Lombès,<sup>3</sup> and the investigators of the MNGIE project

<sup>1</sup>CHU Grenoble-Alpes, F-38000, Grenoble, France; <sup>2</sup>CHU Lyon, Groupe Hospitalier Est, Centre de biologie et Pathologie Est, F-69500, Bron, France; and <sup>3</sup>INSERM U1016, CNRS UMR 8104, Université Paris 5, F-75014, Paris, France

# Overcoming the many hurdles between proof-of-concept and a clinical trial of a MNGIE gene therapy



Innovation Hubs for  
**Gene Therapies**

1. Funding
2. Manufacturing
3. Regulatory approvals
4. Pre-clinical toxicity and biodistribution studies
5. Natural history data
6. Phase I/II Clinical trial
7. Route to Market



**NIHR** | Cambridge Biomedical Research Centre



**PIERRE PONT**  
THERAPEUTICS

*Lily*

**LifeArc**



**UKRI**  
UK Research and Innovation



**UNIVERSITY OF CAMBRIDGE**  
Department of Clinical Neurosciences

Cambridge Academy of Therapeutic Sciences

# MNGIE Natural history study




Ignazio Arena  
with Caterina Garone, Bologna

## Inclusion criteria


1. Have laboratory-confirmed TP deficiency:
  - a) Homozygous or compound heterozygous known pathogenic mutations in the TYMP gene; and/or
  - b) Decreased TP enzyme activity <20% of normal, increased plasma Thd > 2 µmol/L, or increased plasma dUrd > 5 µmol/L.
2. Be aged 5 or over on day that study consent is obtained.
3. Able/willing to provide informed consent (or parent/guardian)

In parallel to US-based NH study led by Michio Hirano (NAMDC7402) and Genomit





Do get in touch:  
[jv361@cam.ac.uk](mailto:jv361@cam.ac.uk)  
[caterina.garone@unibo.it](mailto:caterina.garone@unibo.it)

# Leber's hereditary optic neuropathy (LHON)




- Acute onset painless central visual loss
- One eye soon followed by the other eye
- 1/50,000 prevalence (but 1/9,000 carriers)
- Males>Females
- Modifiers of penetrance? Smoking?
- Mostly **homoplasmic** mtDNA mutations

# Leigh Syndrome



- Primarily childhood onset
  - Episodic developmental regression, often triggered by metabolic stress: fever, surgery, ...
  - Seizures
  - Movement disorder (ataxia, chorea, spasticity,...)
  - Ophthalmoplegia
  - Respiratory failure
  - Brainstem and basal ganglia signal changes on MRI
  - Broad range of genetic causes (nuclear and mtDNA)



# Useful resources

- [www-neurosciences.medschl.cam.ac.uk/mitocamb/](http://www-neurosciences.medschl.cam.ac.uk/mitocamb/)
- [www.newcastle-mitochondria.com](http://www.newcastle-mitochondria.com)
- Parikh et al, 2015 and 2017: Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society
- Ng et al., 2019: Consensus-based statements for the management of mitochondrial stroke-like episodes
- Chinnery and Keogh, Clinical Mitochondrial Medicine (2<sup>nd</sup> edition in preparation)
- The Lily Foundation  
[www.thelilyfoundation.org.uk](http://www.thelilyfoundation.org.uk)



Fighting Mitochondrial Disease.  
Fighting For Hope!


## Clinical Guidelines

Mitochondrial diseases are an important group of inherited disorders that result in a defective mitochondrial respiratory chain. Despite this, the management of these conditions remains a poorly researched area and there is little expert advice available for the treatment of specific aspects of mitochondrial disease. Multi system involvement is also common and this can pose additional management dilemmas for doctors. The Newcastle Mitochondrial Disease Clinical Guidelines aim to provide expert guidance to health professionals in the management of mitochondrial disease.

Within these pages we aim to offer guidance on specific aspects of mitochondrial disease. We have started by publishing the 'Cardiac Guidelines in Adult Mitochondrial Disease', but will add additional guidelines as soon as they are available. Until then, guidance can be accessed from the Newcastle Mitochondrial Team as it has been in the past, either in The Mitochondrial Clinic or by contacting one of the mitochondrial team directly.

The guidelines have been developed using consensus expert opinion sourced from the National Commissioning Group Service for Rare Mitochondrial Diseases for Adults and Children in Newcastle with associated experts from other hospitals.

## Mitochondrial Consensus Guidelines



# Take home messages (1)

1. Mitochondria have many roles - defects in oxidative phosphorylation cause "mitochondrial disease".
2. Mitochondria contain their own circular genome that undergoes relaxed replication outside the nucleus and is maternally inherited.
3. Mitochondrial disease can be caused by mutations in the nuclear or the mitochondrial genome.
4. One cell contains many copies of mtDNA. Heteroplasmy occurs when a mutation occurs in one or more of these copies.
5. There is a threshold effect for deleterious mtDNA mutations to cause a phenotype

# Take home messages (2)

6. Patterns that raise suspicion of mitochondrial disease: CPEO, diabetes and deafness, optic neuropathy, progressive multisystem conditions, maternal inheritance
7. First-line genomic testing has replaced all other diagnostic tests in most instances of suspected mitochondrial disease.
8. Sometimes, a muscle biopsy is still required, in particular in a patient with CPEO, often caused by heteroplasmic mtDNA mutations that may become undetectable in blood.
9. mtDNA maintenance disorders are nuclear inherited mitochondrial diseases due to mutations in genes required for mtDNA replication.
10. There are lots of useful resources to support diagnosis and management.

# Questions?

jv361@cam.ac.uk



MRC  
Mitochondrial  
Biology Unit



UNIVERSITY OF  
CAMBRIDGE  
Department of Clinical Neurosciences